This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

PioneerRx Selects Elsevier Gold Standard Drug Database

Stocks in this article: ENLRENRUK

PHILADELPHIA, May 19, 2014 /PRNewswire/ --

Replacing existing drug database, Gold Standard Drug Database will provide tools to drive smarter drug decisions and superior decision support 

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced an agreement with PioneerRx Pharmacy Software , a fast-growing pharmacy systems vendor serving independent and small chain pharmacies. PioneerRx selected Elsevier's Gold Standard Drug Database to replace its existing drug database and provide current and accurate drug content to enhance its member products, including an alert system, and concise, complete patient education information.

With more than 1,500 retail pharmacy customers nationwide currently using the software in their pharmacies, PioneerRx selected Elsevier to help the organization and its customers improve patient safety and outcomes by providing information to pharmacists such as important drug interaction alerts, dosage parameters, drug pricing and image verification.

"After working with another module of Gold Standard Drug Database, we determined that our entire system could greatly benefit from having the most current drug information," said Jeff Key, Managing Director, PioneerRx. "Our goal of providing the most innovative technology to our patients will be reinforced with Elsevier's user-friendly drug information sheets, available in multiple languages and formatted to help consumers make educated decisions about their health and medications."

The Gold Standard Drug Database content is updated daily and has a peer-reviewed editorial process in place to ensure the highest accuracy of drug product information, drug pricing, clinical and patient education information. PioneerRx will benefit from the database's modern technical architecture, accurate content, built-in human logic and flexible implementation, all of which drive smarter drug decisions in pharmacies.

"PioneerRx shows how the superior technology of Gold Standard Drug Database makes a full replacement of another solution easy and worthwhile, even for technology vendor systems that integrate client data," said Trygve Anderson, R.Ph., Vice President, Pharmacy Solutions, Elsevier Clinical Solutions. "PioneerRx is expanding rapidly and we're looking forward to working closely with the organization to ensure that Gold Standard Drug Database continues to exceed their expectations and those of the pharmacies they serve."

For more information about Elsevier Gold Standard, go to:  http://www.goldstandard.com

About Elsevier 

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions - among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey -  and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media Contact Christopher Capot Director, Corporate Relations Elsevier +1-212-633-3164 c.capot@elsevier.com

SOURCE Elsevier

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs